MedPath

Treating tinea cruris with satt e barg panwad.

Phase 2
Conditions
Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
Registration Number
CTRI/2024/08/071845
Lead Sponsor
shiba fathima
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patient diagnosed with tinea cruris (skin of the genitals, inner thighs and buttocks) clinically

as well as by KOH mount test without nail and scalp involvement.

Patient not taking any other drugs for tinea cruris.

Patient who are willing and able to provide informed consent.

Patient who are willing and able to understand and follow the protocol for the duration of the

study.

Exclusion Criteria

1. Presence of complications such as secondary bacterial infection of the lesions.

2. Patients of tinea at other parts of body except tinea cruris.

3. Patients already on topical and/or systemic antifungal treatment (1 week of topical therapy and/or 4 weeks of systemic antifungal therapy before baseline visit)

4. patients with uncontrolled diabetes.

5. Immunosuppressant patients like AIDS/HIV infection.

6. pregnant and lactating women.

7. Noncompliance with the trial protocol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Change in Investigator’s global assessment(IGA) <br/ ><br>2. Mycological cure: Clinically suspected cases of tinea cruris will be confirmed by skin scraping and KOH preparation, by visualizing presence or absence of long, narrow, septate and branching hyphae under microscope at baseline and at the conclusion of trial.Timepoint: at the baseline and at 6 week
Secondary Outcome Measures
NameTimeMethod
1. Change in TCS (Total clinical score. <br/ ><br>2. Changes in Dermatology Life Quality Index.Timepoint: at the end of treatment
© Copyright 2025. All Rights Reserved by MedPath